


We Claim:

1. A compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R¹ is H, OH, OC₁₋₃alkyl, C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH, or OC₁₋₃alkyl;

R² is H, halogen, C₁₋₃alkyl, CONR⁵R⁶, S(=O)_mC₁₋₃alkyl, S(=O)₂NR⁵R⁶, C₁₋₃alkyl substituted optionally with OH, or OC₁₋₃alkyl;

R³, R⁴ are independently H, C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁵, R⁶ are independently H, C₁₋₃alkyl, C₂₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, or

R⁵ and R⁶ can be joined together with saturated carbon atoms to form a 5 or 6 membered ring and said carbon atoms can be either unsubstituted or substituted optionally with C₁₋₃alkyl, C₂₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;


R⁷, R⁸ are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected from N, O, S, such as pyrrolidine, piperidine, Δ³-piperidine, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl, or substituted on nitrogen with C₁₋₄alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl;

n is 2 to 4;

m is 0, 1 or 2

and any pharmaceutically acceptable salts and solvates.

2. A compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R¹ is H, C₁₋₅alkyl, C₃₋₅alkenyl, an aromatic ring such as phenyl, thienyl, pyridyl, and imidazolyl which is either unsubstituted or substituted optionally with OH, OC₁₋₃alkyl, S(=O)_mC₁₋₃alkyl, halogen, CF₃, or S(=O)₂NR⁵R⁶; or C₂₋₅alkyl substituted optionally with OH, OC₁₋₃alkyl, S(=O)_mC₁₋₃alkyl or an aromatic ring such as phenyl, thienyl, pyridyl, and imidazolyl which is either unsubstituted or substituted optionally with OH, OC₁₋₃alkyl, S(=O)_mC₁₋₃alkyl, halogen, CF₃, S(=O)₂NR⁵R⁶; or C₃₋₅alkenyl substituted optionally with OH, OC₁₋₃alkyl, or S(=O)_mC₁₋₃alkyl;

R² is H, halogen, C₁₋₃alkyl, S(=O)_mC₁₋₃alkyl, S(=O)₂NR⁵R⁶, or C₁₋₃alkyl substituted optionally with OH, or OC₁₋₃alkyl;

R³ & R⁴ are independently H, C₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁵, R⁶ are independently H, C₁₋₃alkyl, C₂₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, or R⁵ and R⁶ can be joined together with saturated carbon atoms to form a 5 or 6 membered ring and said carbon atoms can be either unsubstituted or substituted optionally with C₁₋₃alkyl, C₂₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁷, R⁸ are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected from N, O, S, such as pyrrolidine, piperidine, Δ³-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, phenyl which can be unsubstituted or substituted

Sub
A2


optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl, or substituted on nitrogen with C₁₋₄alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl;

n is 2 to 4;

m is 0, 1 or 2

and any pharmaceutically acceptable salts and solvates.

3. A compound of the formula:



R³ & R⁴ are independently H, C₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁷, R⁸ are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected from N, O, S, such as pyrrolidine, piperidine, Δ³-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl, or substituted on nitrogen with C₁₋₄alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl;


R⁹ is phenyl or a monocyclic heteroaromatic ring which can be unsubstituted or substituted with C₁₋₄ alkyl, halogen, OC₁₋₄alkyl;

R¹⁰ is C₁₋₄alkyl, or R¹⁰ can be joined to R⁹ to form a fused bicyclic ring system such as indoline;

n is 2 to 4

and any pharmaceutically acceptable salts and solvates.

4. A Compound of the formula:



5 R^3 & R^4 are independently H, C_{1-3} alkyl, or C_{1-3} alkyl substituted optionally with OH or OC_{1-3} alkyl;

R^7 , R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected from N, O, S, such as pyrrolidine, piperidine, Δ^3 -piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3} alkyl, C_{1-3} alkyl substituted optionally with OH, OC_{1-3} alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF_3 , OC_{1-3} alkyl, or C_{1-3} alkyl, or substituted on nitrogen with C_{1-4} alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3 , OC_{1-3} alkyl, or C_{1-3} alkyl;


R^{11} is C_{1-3} alkyl, phenyl or a monocyclic heteroaromatic ring which can be unsubstituted or substituted with C_{1-4} alkyl, halogen, OC_{1-4} alkyl;

R^{12} is C_{1-4} alkyl or a fused bicyclic heteroaromatic ring such as thieno[3,2-*e*]-1,2-thiazine, or 1,2-benzothiazine, or R^{12} can be joined to R^{11} to form a fused bicyclic ring system such as 2,3-dihydro-benzo[*c*]isoxazole;

n is 2 to 4

and any pharmaceutically acceptable salts and solvates.

5. A method for lowering IOP which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R¹ is H, OH, OC₁₋₃alkyl, C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH, or OC₁₋₃alkyl;

R² is H, halogen, C₁₋₃alkyl, CONR⁵R⁶, S(=O)_mC₁₋₃alkyl, S(=O)₂NR⁵R⁶, C₁₋₃alkyl substituted optionally with OH, or OC₁₋₃alkyl;

R³, R⁴ are independently H, C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁵, R⁶ are independently H, C₁₋₃alkyl, C₂₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, or

R⁵ and R⁶ can be joined together with saturated carbon atoms to form a 5 or 6

membered ring and said carbon atoms can be either unsubstituted or substituted

optionally with C₁₋₃alkyl, C₂₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁷, R⁸ are together with the nitrogen atom to which they are attached incorporated into a

heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected

from N, O, S, such as pyrrolidine, piperidine, Δ³-piperidine, piperazine, morpholine

or thiomorpholine which can be unsubstituted or substituted on carbon with one or

more substituents optionally selected from C₁₋₃alkyl, C₁₋₃alkyl substituted

optionally with OH, OC₁₋₃alkyl, phenyl which can be unsubstituted or substituted

optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl, or substituted on nitrogen

with C₁₋₄alkoxy or phenyl which can be unsubstituted or substituted optionally with


halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl;

n is 2 to 4;

m is 0, 1 or 2

and any pharmaceutically acceptable salts and solvates.

6. A method for lowering IOP which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R^1 is H, C_{1-5} alkyl, C_{3-5} alkenyl, an aromatic ring such as phenyl, thienyl, pyridyl, and imidazolyl which is either unsubstituted or substituted optionally with OH, OC_{1-3} alkyl, $S(=O)_m C_{1-3}$ alkyl, halogen, CF_3 , or $S(=O)_2 NR^5 R^6$; or C_{2-5} alkyl substituted optionally with OH, OC_{1-3} alkyl, $S(=O)_m C_{1-3}$ alkyl or an aromatic ring such as phenyl, thienyl, pyridyl, and imidazolyl which is either unsubstituted or substituted optionally with OH, OC_{1-3} alkyl, $S(=O)_m C_{1-3}$ alkyl, halogen, CF_3 , $S(=O)_2 NR^5 R^6$; or C_{3-5} alkenyl substituted optionally with OH, OC_{1-3} alkyl, or $S(=O)_m C_{1-3}$ alkyl;

R^2 is H, halogen, C_{1-3} alkyl, $S(=O)_m C_{1-3}$ alkyl, $S(=O)_2 NR^5 R^6$, or C_{1-3} alkyl substituted optionally with OH, or OC_{1-3} alkyl;

R^3 & R^4 are independently H, C_{1-3} alkyl, or C_{1-3} alkyl substituted optionally with OH or OC_{1-3} alkyl;

R^5 , R^6 are independently H, C_{1-3} alkyl, C_{2-3} alkyl substituted optionally with OH, OC_{1-3} alkyl, or R^5 and R^6 can be joined together with saturated carbon atoms to form a 5 or 6 membered ring and said carbon atoms can be either unsubstituted or substituted optionally with C_{1-3} alkyl, C_{2-3} alkyl substituted optionally with OH or OC_{1-3} alkyl;

R^7 , R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected from N, O, S, such as pyrrolidine, piperidine, Δ^3 -piperidine, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or

Sub
A³


more substituents optionally selected from C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl, or substituted on nitrogen with C₁₋₄alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl;

n is 2 to 4;

m is 0, 1 or 2

and any pharmaceutically acceptable salts and solvates.

7. A method for lowering IOP which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



R³ & R⁴ are independently H, C₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁷, R⁸ are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected from N, O, S, such as pyrrolidine, piperidine, Δ³-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl, or substituted on nitrogen with C₁₋₄alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl;


R⁹ is phenyl or a monocyclic heteroaromatic ring which can be unsubstituted or substituted with C₁₋₄ alkyl, halogen, OC₁₋₄alkyl;

R¹⁰ is C₁₋₄alkyl, or R¹⁰ can be joined to R⁹ to form a fused bicyclic ring system such as indoline;

n is 2 to 4

and any pharmaceutically acceptable salts and solvates.

8. A method for lowering IOP which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



R^3 & R^4 are independently H, C_{1-3} alkyl, or C_{1-3} alkyl substituted optionally with OH or OC_{1-3} alkyl;

R^7 , R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected from N, O, S, such as pyrrolidine, piperidine, Δ^3 -piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3} alkyl, C_{1-3} alkyl substituted optionally with OH, OC_{1-3} alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF_3 , OC_{1-3} alkyl, or C_{1-3} alkyl, or substituted on nitrogen with C_{1-4} alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3 , OC_{1-3} alkyl, or C_{1-3} alkyl;


R^{11} is C_{1-3} alkyl, phenyl or a monocyclic heteroaromatic ring which can be unsubstituted or substituted with C_{1-4} alkyl, halogen, OC_{1-4} alkyl;

R^{12} is C_{1-4} alkyl or a fused bicyclic heteroaromatic ring such as thieno[3,2-*e*]-1,2-thiazine, or 1,2-benzothiazine, or R^{12} can be joined to R^{11} to form a fused bicyclic ring system such as 2,3-dihydro-benzo[*c*]isoxazole;

n is 2 to 4

and any pharmaceutically acceptable salts and solvates.

9. A method for improving blood flow to the optic nerve head and the retina which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R^1 is H, OH, $OC_{1-3}alkyl$, $C_{1-3}alkyl$, $C_{1-3}alkyl$ substituted optionally with OH, or $OC_{1-3}alkyl$;

R^2 is H, halogen, $C_{1-3}alkyl$, $CONR^5R^6$, $S(=O)_mC_{1-3}alkyl$, $S(=O)_2NR^5R^6$, $C_{1-3}alkyl$ substituted optionally with OH, or $OC_{1-3}alkyl$;

R^3 , R^4 are independently H, $C_{1-3}alkyl$, $C_{1-3}alkyl$ substituted optionally with OH or $OC_{1-3}alkyl$;

R^5 , R^6 are independently H, $C_{1-3}alkyl$, $C_{2-3}alkyl$ substituted optionally with OH, $OC_{1-3}alkyl$, or

R^5 and R^6 can be joined together with saturated carbon atoms to form a 5 or 6 membered ring and said carbon atoms can be either unsubstituted or substituted optionally with $C_{1-3}alkyl$, $C_{2-3}alkyl$ substituted optionally with OH or $OC_{1-3}alkyl$;


R^7 , R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected from N, O, S, such as pyrrolidine, piperidine, Δ^3 -piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from $C_{1-3}alkyl$, $C_{1-3}alkyl$ substituted optionally with OH, $OC_{1-3}alkyl$, phenyl which can be unsubstituted or substituted optionally with halogen, CF_3 , $OC_{1-3}alkyl$, or $C_{1-3}alkyl$, or substituted on nitrogen with $C_{1-4}alkoxy$ or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3 , $OC_{1-3}alkyl$, or $C_{1-3}alkyl$;

n is 2 to 4;

m is 0, 1 or 2

and any pharmaceutically acceptable salts and solvates.

10. A method for improving blood flow to the optic nerve head and the retina which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R^1 is H, C_{1-5} alkyl, C_{3-5} alkenyl, an aromatic ring such as phenyl, thienyl, pyridyl, and imidazolyl which is either unsubstituted or substituted optionally with OH, OC_{1-3} alkyl, $S(=O)_mC_{1-3}$ alkyl, halogen, CF_3 , or $S(=O)_2NR^5R^6$; or C_{2-5} alkyl substituted optionally with OH, OC_{1-3} alkyl, $S(=O)_mC_{1-3}$ alkyl or an aromatic ring such as phenyl, thienyl, pyridyl, and imidazolyl which is either unsubstituted or substituted optionally with OH, OC_{1-3} alkyl, $S(=O)_mC_{1-3}$ alkyl, halogen, CF_3 , $S(=O)_2NR^5R^6$; or C_{3-5} alkenyl substituted optionally with OH, OC_{1-3} alkyl, or $S(=O)_mC_{1-3}$ alkyl;

R^2 is H, halogen, C_{1-3} alkyl, $S(=O)_mC_{1-3}$ alkyl, $S(=O)_2NR^5R^6$, or C_{1-3} alkyl substituted optionally with OH, or OC_{1-3} alkyl;

R^3 & R^4 are independently H, C_{1-3} alkyl, or C_{1-3} alkyl substituted optionally with OH or OC_{1-3} alkyl;

R^5 , R^6 are independently H, C_{1-3} alkyl, C_{2-3} alkyl substituted optionally with OH, OC_{1-3} alkyl, or R^5 and R^6 can be joined together with saturated carbon atoms to form a 5 or 6 membered ring and said carbon atoms can be either unsubstituted or substituted optionally with C_{1-3} alkyl, C_{2-3} alkyl substituted optionally with OH or OC_{1-3} alkyl;

R^7 , R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected from N, O, S, such as pyrrolidine, piperidine, Δ^3 -piperidine, piperazine, morpholine

Sub
A4
5

or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl, or substituted on nitrogen with C₁₋₄alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl;


n is 2 to 4;

m is 0, 1 or 2

and any pharmaceutically acceptable salts and solvates.

10

11. A method for improving blood flow to the optic nerve head and the retina which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



15

R³ & R⁴ are independently H, C₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁷, R⁸ are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected from N, O, S, such as pyrrolidine, piperidine, Δ³-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl, or substituted on nitrogen with C₁₋₄alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl;

20

25


R^9 is phenyl or a monocyclic heteroaromatic ring which can be unsubstituted or substituted with C_{1-4} alkyl, halogen, OC_{1-4} alkyl;

R^{10} is C_{1-4} alkyl, or R^{10} can be joined to R^9 to form a fused bicyclic ring system such as indoline;

n is 2 to 4

and any pharmaceutically acceptable salts and solvates.

12. A method for improving blood flow to the optic nerve head and the retina which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



R^3 & R^4 are independently H, C_{1-3} alkyl, or C_{1-3} alkyl substituted optionally with OH or OC_{1-3} alkyl;

R^7 , R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected from N, O, S, such as pyrrolidine, piperidine, Δ^3 -piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3} alkyl, C_{1-3} alkyl substituted optionally with OH, OC_{1-3} alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF_3 , OC_{1-3} alkyl, or C_{1-3} alkyl, or substituted on nitrogen with C_{1-4} alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3 , OC_{1-3} alkyl, or C_{1-3} alkyl;


R^{11} is C_{1-3} alkyl, phenyl or a monocyclic heteroaromatic ring which can be unsubstituted or substituted with C_{1-4} alkyl, halogen, OC_{1-4} alkyl;

R^{12} is C_{1-4} alkyl or a fused bicyclic heteroaromatic ring such as thieno[3,2-e]-1,2-thiazine, or 1,2-benzothiazine, or R^{12} can be joined to R^{11} to form a fused bicyclic ring system such as 2,3-dihydro-benzo[c]isoxazole;

n is 2 to 4

and any pharmaceutically acceptable salts and solvates.

13. A method for treating retinal diseases which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R¹ is H, OH, OC₁₋₃alkyl, C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH, or OC₁₋₃alkyl;

R² is H, halogen, C₁₋₃alkyl, CONR⁵R⁶, S(=O)_mC₁₋₃alkyl, S(=O)₂NR⁵R⁶, C₁₋₃alkyl substituted optionally with OH, or OC₁₋₃alkyl;

R³, R⁴ are independently H, C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁵, R⁶ are independently H, C₁₋₃alkyl, C₂₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, or

R⁵ and R⁶ can be joined together with saturated carbon atoms to form a 5 or 6 membered ring and said carbon atoms can be either unsubstituted or substituted optionally with C₁₋₃alkyl, C₂₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;


R⁷, R⁸ are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected from N, O, S, such as pyrrolidine, piperidine, Δ³-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl, or substituted on nitrogen with C₁₋₄alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl;

n is 2 to 4;

m is 0, 1 or 2

and any pharmaceutically acceptable salts and solvates.

14. A method for treating retinal diseases which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R¹ is H, C₁₋₅alkyl, C₃₋₅alkenyl, an aromatic ring such as phenyl, thienyl, pyridyl, and imidazolyl which is either unsubstituted or substituted optionally with OH, OC₁₋₃alkyl, S(=O)_mC₁₋₃alkyl, halogen, CF₃, or S(=O)₂NR⁵R⁶; or C₂₋₅alkyl substituted optionally with OH, OC₁₋₃alkyl, S(=O)_mC₁₋₃alkyl or an aromatic ring such as phenyl, thienyl, pyridyl, and imidazolyl which is either unsubstituted or substituted optionally with OH, OC₁₋₃alkyl, S(=O)_mC₁₋₃alkyl, halogen, CF₃, S(=O)₂NR⁵R⁶; or C₃₋₅alkenyl substituted optionally with OH, OC₁₋₃alkyl, or S(=O)_mC₁₋₃alkyl;

R² is H, halogen, C₁₋₃alkyl, S(=O)_mC₁₋₃alkyl, S(=O)₂NR⁵R⁶, or C₁₋₃alkyl substituted optionally with OH, or OC₁₋₃alkyl;

R³ & R⁴ are independently H, C₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁵, R⁶ are independently H, C₁₋₃alkyl, C₂₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, or R⁵ and R⁶ can be joined together with saturated carbon atoms to form a 5 or 6 membered ring and said carbon atoms can be either unsubstituted or substituted optionally with C₁₋₃alkyl, C₂₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁷, R⁸ are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected


Sub
AS
5 from N, O, S, such as pyrrolidine, piperidine, Δ^3 -piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3} alkyl, C_{1-3} alkyl substituted optionally with OH, OC_{1-3} alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF_3 , OC_{1-3} alkyl, or C_{1-3} alkyl, or substituted on nitrogen with C_{1-4} alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3 , OC_{1-3} alkyl, or C_{1-3} alkyl;

n is 2 to 4;

m is 0, 1 or 2

10 and any pharmaceutically acceptable salts and solvates.

15 15. A method for treating retinal diseases which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:




15 R^3 & R^4 are independently H, C_{1-3} alkyl, or C_{1-3} alkyl substituted optionally with OH or OC_{1-3} alkyl;

20 R^7 , R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected from N, O, S, such as pyrrolidine, piperidine, Δ^3 -piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3} alkyl, C_{1-3} alkyl substituted optionally with OH, OC_{1-3} alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF_3 , OC_{1-3} alkyl, or C_{1-3} alkyl, or substituted on nitrogen
25 with C_{1-4} alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3 , OC_{1-3} alkyl, or C_{1-3} alkyl;

R^9 is phenyl or a monocyclic heteroaromatic ring which can be unsubstituted or substituted with C_{1-4} alkyl, halogen, OC_{1-4} alkyl;

R^{10} is C_{1-4} alkyl, or R^{10} can be joined to R^9 to form a fused bicyclic ring system such as indoline;
 n is 2 to 4
 and any pharmaceutically acceptable salts and solvates.

16. A method for treating retinal diseases which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:



R^3 & R^4 are independently H, C_{1-3} alkyl, or C_{1-3} alkyl substituted optionally with OH or OC_{1-3} alkyl;

R^7 , R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected from N, O, S, such as pyrrolidine, piperidine, Δ^3 -piperidine, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3} alkyl, C_{1-3} alkyl substituted optionally with OH, OC_{1-3} alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF_3 , OC_{1-3} alkyl, or C_{1-3} alkyl, or substituted on nitrogen with C_{1-4} alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3 , OC_{1-3} alkyl, or C_{1-3} alkyl;


R^{11} is C_{1-3} alkyl, phenyl or a monocyclic heteroaromatic ring which can be unsubstituted or substituted with C_{1-4} alkyl, halogen, OC_{1-4} alkyl;

R^{12} is C_{1-4} alkyl or a fused bicyclic heteroaromatic ring such as thieno[3,2-*e*]-1,2-thiazine, or 1,2-benzothiazine, or R^{12} can be joined to R^{11} to form a fused bicyclic ring system such as 2,3-dihydro-benzo[*c*]isoxazole;

n is 2 to 4

and any pharmaceutically acceptable salts and solvates.

17. A composition for lowering IOP comprising a pharmaceutically effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R¹ is H, OH, OC₁₋₃alkyl, C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH, or OC₁₋₃alkyl;

R² is H, halogen, C₁₋₃alkyl, CONR⁵R⁶, S(=O)ₘC₁₋₃alkyl, S(=O)₂NR⁵R⁶, C₁₋₃alkyl substituted optionally with OH, or OC₁₋₃alkyl;

R³, R⁴ are independently H, C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁵, R⁶ are independently H, C₁₋₃alkyl, C₂₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, or

R⁵ and R⁶ can be joined together with saturated carbon atoms to form a 5 or 6

membered ring and said carbon atoms can be either unsubstituted or substituted

optionally with C₁₋₃alkyl, C₂₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁷, R⁸ are together with the nitrogen atom to which they are attached incorporated into a

heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected

from N, O, S, such as pyrrolidine, piperidine, Δ³-piperidein, piperazine, morpholine

or thiomorpholine which can be unsubstituted or substituted on carbon with one or

more substituents optionally selected from C₁₋₃alkyl, C₁₋₃alkyl substituted

optionally with OH, OC₁₋₃alkyl, phenyl which can be unsubstituted or substituted

optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl, or substituted on nitrogen

with C₁₋₄alkoxy or phenyl which can be unsubstituted or substituted optionally with


halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl;

n is 2 to 4;

m is 0, 1 or 2

and any pharmaceutically acceptable salts and solvates.

18. A composition for lowering IOP comprising a pharmaceutically effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R^1 is H, C_{1-5} alkyl, C_{3-5} alkenyl, an aromatic ring such as phenyl, thienyl, pyridyl, and imidazolyl which is either unsubstituted or substituted optionally with OH, OC_{1-3} alkyl, $S(=O)_mC_{1-3}$ alkyl, halogen, CF_3 , or $S(=O)_2NR^5R^6$; or C_{2-5} alkyl substituted optionally with OH, OC_{1-3} alkyl, $S(=O)_mC_{1-3}$ alkyl or an aromatic ring such as phenyl, thienyl, pyridyl, and imidazolyl which is either unsubstituted or substituted optionally with OH, OC_{1-3} alkyl, $S(=O)_mC_{1-3}$ alkyl, halogen, CF_3 , $S(=O)_2NR^5R^6$; or C_{3-5} alkenyl substituted optionally with OH, OC_{1-3} alkyl, or $S(=O)_mC_{1-3}$ alkyl;

R^2 is H, halogen, C_{1-3} alkyl, $S(=O)_mC_{1-3}$ alkyl, $S(=O)_2NR^5R^6$, or C_{1-3} alkyl substituted optionally with OH, or OC_{1-3} alkyl;

R^3 & R^4 are independently H, C_{1-3} alkyl, or C_{1-3} alkyl substituted optionally with OH or OC_{1-3} alkyl;

R^5 , R^6 are independently H, C_{1-3} alkyl, C_{2-3} alkyl substituted optionally with OH, OC_{1-3} alkyl, or R^5 and R^6 can be joined together with saturated carbon atoms to form a 5 or 6 membered ring and said carbon atoms can be either unsubstituted or substituted optionally with C_{1-3} alkyl, C_{2-3} alkyl substituted optionally with OH or OC_{1-3} alkyl;

R^7 , R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected from N, O, S, such as pyrrolidine, piperidine, Δ^3 -piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or


Sub
A6

S

m is 0, 1 or 2

and any pharmaceutically acceptable salts and solvates.

10



15

20

25


R¹⁰ is C₁₋₄alkyl, or R¹⁰ can be joined to R⁹ to form a fused bicyclic ring system such as indoline;

2006-2007 P.L. 110-181

n is 2 to 4

and any pharmaceutically acceptable salts and solvates.

20. A composition for lowering IOP comprising a pharmaceutically effective amount
of a compound of the formula:



R³ & R⁴ are independently H, C₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁷, R⁸ are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected from N, O, S, such as pyrrolidine, piperidine, Δ³-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl, or substituted on nitrogen with C₁₋₄alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl;

R¹¹ is C₁₋₃alkyl, phenyl or a monocyclic heteroaromatic ring which can be unsubstituted or substituted with C₁₋₄alkyl, halogen, OC₁₋₄alkyl;


R¹² is C₁₋₄alkyl or a fused bicyclic heteroaromatic ring such as thieno[3,2-e]-1,2-thiazine, or 1,2-benzothiazine, or R¹² can be joined to R¹¹ to form a fused bicyclic ring system such as 2,3-dihydro-benzo[c]isoxazole;

n is 2 to 4

and any pharmaceutically acceptable salts and solvates.

21. A composition for improving blood flow to the optic nerve head and the retina comprising a pharmaceutically effective amount of a compound of the formula:

Sub
A7



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R^1 is H, OH, $OC_{1-3}alkyl$, $C_{1-3}alkyl$, $C_{1-3}alkyl$ substituted optionally with OH, or $OC_{1-3}alkyl$;

R^2 is H, halogen, $C_{1-3}alkyl$, $CONR^5R^6$, $S(=O)_mC_{1-3}alkyl$, $S(=O)_2NR^5R^6$, $C_{1-3}alkyl$ substituted optionally with OH, or $OC_{1-3}alkyl$;

R^3 , R^4 are independently H, $C_{1-3}alkyl$, $C_{1-3}alkyl$ substituted optionally with OH or $OC_{1-3}alkyl$;

R^5 , R^6 are independently H, $C_{1-3}alkyl$, $C_{2-3}alkyl$ substituted optionally with OH, $OC_{1-3}alkyl$, or

R^5 and R^6 can be joined together with saturated carbon atoms to form a 5 or 6

membered ring and said carbon atoms can be either unsubstituted or substituted

optionally with $C_{1-3}alkyl$, $C_{2-3}alkyl$ substituted optionally with OH or $OC_{1-3}alkyl$;

R^7 , R^8 are together with the nitrogen atom to which they are attached incorporated into a

heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected

from N, O, S, such as pyrrolidine, piperidine, Δ^3 -piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or

more substituents optionally selected from $C_{1-3}alkyl$, $C_{1-3}alkyl$ substituted

optionally with OH, $OC_{1-3}alkyl$, phenyl which can be unsubstituted or substituted

optionally with halogen, CF_3 , $OC_{1-3}alkyl$, or $C_{1-3}alkyl$, or substituted on nitrogen

with $C_{1-4}alkoxy$ or phenyl which can be unsubstituted or substituted optionally with


halogen, CF_3 , $OC_{1-3}alkyl$, or $C_{1-3}alkyl$;

n is 2 to 4;

m is 0, 1 or 2

and any pharmaceutically acceptable salts and solvates.

22. A composition for improving blood flow to the optic nerve head and the retina comprising a pharmaceutically effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R¹ is H, C₁₋₅alkyl, C₃₋₅alkenyl, an aromatic ring such as phenyl, thienyl, pyridyl, and imidazolyl which is either unsubstituted or substituted optionally with OH, OC₁₋₃alkyl, S(=O)_mC₁₋₃alkyl, halogen, CF₃, or S(=O)₂NR⁵R⁶; or C₂₋₅alkyl substituted optionally with OH, OC₁₋₃alkyl, S(=O)_mC₁₋₃alkyl or an aromatic ring such as phenyl, thienyl, pyridyl, and imidazolyl which is either unsubstituted or substituted optionally with OH, OC₁₋₃alkyl, S(=O)_mC₁₋₃alkyl, halogen, CF₃, S(=O)₂NR⁵R⁶; or C₃₋₅alkenyl substituted optionally with OH, OC₁₋₃alkyl, or S(=O)_mC₁₋₃alkyl;

R² is H, halogen, C₁₋₃alkyl, S(=O)_mC₁₋₃alkyl, S(=O)₂NR⁵R⁶, or C₁₋₃alkyl substituted optionally with OH, or OC₁₋₃alkyl;

R³ & R⁴ are independently H, C₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁵, R⁶ are independently H, C₁₋₃alkyl, C₂₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, or R⁵ and R⁶ can be joined together with saturated carbon atoms to form a 5 or 6 membered ring and said carbon atoms can be either unsubstituted or substituted optionally with C₁₋₃alkyl, C₂₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁷, R⁸ are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected from N, O, S, such as pyrrolidine, piperidine, Δ³-piperidine, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl, or substituted on nitrogen


with C₁₋₄alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl;

n is 2 to 4;

m is 0, 1 or 2

and any pharmaceutically acceptable salts and solvates.

23. A composition for improving blood flow to the optic nerve head and the retina comprising a pharmaceutically effective amount of a compound of the formula:



R³ & R⁴ are independently H, C₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁷, R⁸ are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected from N, O, S, such as pyrrolidine, piperidine, Δ³-piperidine, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl, or substituted on nitrogen with C₁₋₄alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl;


R⁹ is phenyl or a monocyclic heteroaromatic ring which can be unsubstituted or substituted with C₁₋₄ alkyl, halogen, OC₁₋₄alkyl;

R¹⁰ is C₁₋₄alkyl, or R¹⁰ can be joined to R⁹ to form a fused bicyclic ring system such as indoline;

n is 2 to 4

and any pharmaceutically acceptable salts and solvates.

24. A composition for improving blood flow to the optic nerve head and the retina comprising a pharmaceutically effective amount of a Compound of the formula:



R^3 & R^4 are independently H, C_{1-3} alkyl, or C_{1-3} alkyl substituted optionally with OH or OC_{1-3} alkyl;

R^7 , R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected from N, O, S, such as pyrrolidine, piperidine, Δ^3 -piperidine, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3} alkyl, C_{1-3} alkyl substituted optionally with OH, OC_{1-3} alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF_3 , OC_{1-3} alkyl, or C_{1-3} alkyl, or substituted on nitrogen with C_{1-4} alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3 , OC_{1-3} alkyl, or C_{1-3} alkyl;


R^{11} is C_{1-3} alkyl, phenyl or a monocyclic heteroaromatic ring which can be unsubstituted or substituted with C_{1-4} alkyl, halogen, OC_{1-4} alkyl;

R^{12} is C_{1-4} alkyl or a fused bicyclic heteroaromatic ring such as thieno[3,2-*e*]-1,2-thiazine, or 1,2-benzothiazine, or R^{12} can be joined to R^{11} to form a fused bicyclic ring system such as 2,3-dihydro-benzo[*c*]isoxazole;

n is 2 to 4

and any pharmaceutically acceptable salts and solvates.

25. A composition for treating retinal diseases comprising a pharmaceutically effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R¹ is H, OH, OC₁₋₃alkyl, C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH, or OC₁₋₃alkyl;

R² is H, halogen, C₁₋₃alkyl, CONR⁵R⁶, S(=O)_mC₁₋₃alkyl, S(=O)₂NR⁵R⁶, C₁₋₃alkyl substituted optionally with OH, or OC₁₋₃alkyl;

R³, R⁴ are independently H, C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁵, R⁶ are independently H, C₁₋₃alkyl, C₂₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, or

R⁵ and R⁶ can be joined together with saturated carbon atoms to form a 5 or 6 membered ring and said carbon atoms can be either unsubstituted or substituted optionally with C₁₋₃alkyl, C₂₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;


R⁷, R⁸ are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected from N, O, S, such as pyrrolidine, piperidine, Δ³-piperidine, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl, or substituted on nitrogen with C₁₋₄alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl;

n is 2 to 4;

m is 0, 1 or 2

and any pharmaceutically acceptable salts and solvates.

26. A composition for treating retinal diseases comprising a pharmaceutically effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R¹ is H, C₁₋₅alkyl, C₃₋₅alkenyl, an aromatic ring such as phenyl, thienyl, pyridyl, and imidazolyl which is either unsubstituted or substituted optionally with OH, OC₁₋₃alkyl, S(=O)_mC₁₋₃alkyl, halogen, CF₃, or S(=O)₂NR⁵R⁶; or C₂₋₅alkyl substituted optionally with OH, OC₁₋₃alkyl, S(=O)_mC₁₋₃alkyl or an aromatic ring such as phenyl, thienyl, pyridyl, and imidazolyl which is either unsubstituted or substituted optionally with OH, OC₁₋₃alkyl, S(=O)_mC₁₋₃alkyl, halogen, CF₃, S(=O)₂NR⁵R⁶; or C₃₋₅alkenyl substituted optionally with OH, OC₁₋₃alkyl, or S(=O)_mC₁₋₃alkyl;

R² is H, halogen, C₁₋₃alkyl, S(=O)_mC₁₋₃alkyl, S(=O)₂NR⁵R⁶, or C₁₋₃alkyl substituted optionally with OH, or OC₁₋₃alkyl;

R³ & R⁴ are independently H, C₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁵, R⁶ are independently H, C₁₋₃alkyl, C₂₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, or R⁵ and R⁶ can be joined together with saturated carbon atoms to form a 5 or 6 membered ring and said carbon atoms can be either unsubstituted or substituted optionally with C₁₋₃alkyl, C₂₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁷, R⁸ are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected from N, O, S, such as pyrrolidine, piperidine, Δ³-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl, or substituted on nitrogen


with C₁₋₄alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl;

n is 2 to 4;

m is 0, 1 or 2

and any pharmaceutically acceptable salts and solvates.

27. A composition for treating retinal diseases comprising a pharmaceutically effective amount of a compound of the formula:



R³ & R⁴ are independently H, C₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁷, R⁸ are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected from N, O, S, such as pyrrolidine, piperidine, Δ³-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl, or substituted on nitrogen with C₁₋₄alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl;


R⁹ is phenyl or a monocyclic heteroaromatic ring which can be unsubstituted or substituted with C₁₋₄ alkyl, halogen, OC₁₋₄alkyl;

R¹⁰ is C₁₋₄alkyl, or R¹⁰ can be joined to R⁹ to form a fused bicyclic ring system such as indoline;

n is 2 to 4

and any pharmaceutically acceptable salts and solvates.

28. A composition for treating retinal diseases comprising a pharmaceutically effective amount of a compound of the formula:



R³ & R⁴ are independently H, C₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁷, R⁸ are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected from N, O, S, such as pyrrolidine, piperidine, Δ³-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl, or substituted on nitrogen with C₁₋₄alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl;

R¹¹ is C₁₋₃alkyl, phenyl or a monocyclic heteroaromatic ring which can be unsubstituted or substituted with C₁₋₄ alkyl, halogen, OC₁₋₄alkyl;

R¹² is C₁₋₄alkyl or a fused bicyclic heteroaromatic ring such as thieno[3,2-*e*]-1,2-thiazine, or 1,2-benzothiazine, or R¹² can be joined to R¹¹ to form a fused bicyclic ring system such as 2,3-dihydro-benzo[*c*]isoxazole;

n is 2 to 4

and any pharmaceutically acceptable salts and solvates.

29. A method for improving blood flow to the optic nerve head or the retina which comprises administering to a person in need thereof, a composition comprising a pharmaceutically effective amount of a compound with 5HT₇ receptor affinity.

30. A composition for improving blood flow to the optic nerve head or the retina comprising a pharmaceutically effective amount of a compound with 5HT₇ receptor affinity.

31. A method for providing neuroprotection to the optic nerve head or the retina which comprises administering to a person in need thereof, a composition comprising a pharmaceutically effective amount of a compound with 5HT₇ receptor affinity.

32. A composition for providing neuroprotection to the optic nerve head or the retina comprising a pharmaceutically effective amount of a compound with 5HT₇ receptor affinity.

33. A method for treating retinal diseases which comprises administering to a person in need thereof, a composition comprising a pharmaceutically effective amount of a compound with 5HT₇ receptor affinity.

34. The method of Claim 1 wherein the retinal disease is selected from the group consisting of glaucoma, age related macular degeneration, optic neuritis, ischemic disorders, and retinal edema.


35. A composition for treating retinal diseases comprising a pharmaceutically effective amount of a compound with 5HT₇ receptor affinity.

36. The composition of Claim 35 wherein the retinal diseases are selected from the group consisting of glaucoma, age related macular degeneration, optic neuritis, ischemic disorders, diabetic retinopathy, and retinal edema.

37. A method for lowering IOP which comprises administering to a person in need thereof, a composition comprising a pharmaceutically effective amount of a compound with 5HT₇ receptor affinity.

38. A composition for lowering IOP comprising a pharmaceutically effective amount of a compound with 5HT₇ receptor affinity.

39. A method for treating persons suffering from a sleeping disorder, depression, schizophrenia, anxiety, circadian rhythm disorders, and centrally and peripherally mediated hypertension, which comprises, administering a composition comprising a pharmaceutically effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R^1 is H, OH, $OC_{1-3}alkyl$, $C_{1-3}alkyl$, $C_{1-3}alkyl$ substituted optionally with OH, or $OC_{1-3}alkyl$;

R^2 is H, halogen, $C_{1-3}alkyl$, $CONR^5R^6$, $S(=O)_mC_{1-3}alkyl$, $S(=O)_2NR^5R^6$, $C_{1-3}alkyl$ substituted optionally with OH, or $OC_{1-3}alkyl$;

R^3 , R^4 are independently H, $C_{1-3}alkyl$, $C_{1-3}alkyl$ substituted optionally with OH or $OC_{1-3}alkyl$;

R^5 , R^6 are independently H, $C_{1-3}alkyl$, $C_{2-3}alkyl$ substituted optionally with OH, $OC_{1-3}alkyl$, or

R^5 and R^6 can be joined together with saturated carbon atoms to form a 5 or 6 membered ring and said carbon atoms can be either unsubstituted or substituted optionally with $C_{1-3}alkyl$, $C_{2-3}alkyl$ substituted optionally with OH or $OC_{1-3}alkyl$;

R^7 , R^8 are together with the nitrogen atom to which they are attached incorporated into a


heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected from N, O, S, such as pyrrolidine, piperidine, Δ^3 -piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from $C_{1-3}alkyl$, $C_{1-3}alkyl$ substituted optionally with OH, $OC_{1-3}alkyl$, phenyl which can be unsubstituted or substituted optionally with halogen, CF_3 , $OC_{1-3}alkyl$, or $C_{1-3}alkyl$, or substituted on nitrogen with $C_{1-4}alkoxy$ or phenyl which can be unsubstituted or substituted optionally with halogen, CF_3 , $OC_{1-3}alkyl$, or $C_{1-3}alkyl$;

n is 2 to 4;

m is 0, 1 or 2

and any pharmaceutically acceptable salts and solvates.

40. A method for treating persons suffering from a sleeping disorder, depression, schizophrenia, anxiety, obsessive compulsive disorder, circadian rhythm disorders, and centrally and peripherally mediated hypertension which comprises, administering a composition comprising a pharmaceutically effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R¹ is H, C₁₋₅alkyl, C₃₋₅alkenyl, an aromatic ring such as phenyl, thienyl, pyridyl, and imidazolyl which is either unsubstituted or substituted optionally with OH, OC₁₋₃alkyl, S(=O)_mC₁₋₃alkyl, halogen, CF₃, or S(=O)₂NR⁵R⁶; or C₂₋₅alkyl substituted optionally with OH, OC₁₋₃alkyl, S(=O)_mC₁₋₃alkyl or an aromatic ring such as phenyl, thienyl, pyridyl, and imidazolyl which is either unsubstituted or substituted optionally with OH, OC₁₋₃alkyl, S(=O)_mC₁₋₃alkyl, halogen, CF₃, S(=O)₂NR⁵R⁶; or C₃₋₅alkenyl substituted optionally with OH, OC₁₋₃alkyl, or S(=O)_mC₁₋₃alkyl;

R² is H, halogen, C₁₋₃alkyl, S(=O)_mC₁₋₃alkyl, S(=O)₂NR⁵R⁶, or C₁₋₃alkyl substituted optionally with OH, or OC₁₋₃alkyl;

R³ & R⁴ are independently H, C₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁵, R⁶ are independently H, C₁₋₃alkyl, C₂₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, or R⁵ and R⁶ can be joined together with saturated carbon atoms to form a 5 or 6 membered ring and said carbon atoms can be either unsubstituted or substituted optionally with C₁₋₃alkyl, C₂₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

Sub
A9
5


R⁷, R⁸ are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected from N, O, S, such as pyrrolidine, piperidine, Δ³-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl, or substituted on nitrogen with C₁₋₄alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl;

10 n is 2 to 4;

m is 0, 1 or 2

and any pharmaceutically acceptable salts and solvates.

41. A method for treating persons suffering from a sleeping disorder, depression, schizophrenia, anxiety, obsessive compulsive disorders, circadian rhythm disorders, and centrally and peripherally mediated hypertension which comprises, administering a composition comprising a pharmaceutically effective amount of a compound of the formula:



20 R³ & R⁴ are independently H, C₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

25 R⁷, R⁸ are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected from N, O, S, such as pyrrolidine, piperidine, Δ³-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl, or substituted on nitrogen

with C₁₋₄alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl;


R⁹ is phenyl or a monocyclic heteroaromatic ring which can be unsubstituted or substituted with C₁₋₄ alkyl, halogen, OC₁₋₄alkyl;

R¹⁰ is C₁₋₄alkyl, or R¹⁰ can be joined to R⁹ to form a fused bicyclic ring system such as indoline;

n is 2 to 4

and any pharmaceutically acceptable salts and solvates.

42. A method for treating persons suffering from a sleeping disorder, depression, schizophrenia, anxiety, obsessive compulsive disorder, circadian rhythm disorders, and centrally and peripherally mediated hypertension which comprises, administering a composition comprising a pharmaceutically effective amount of a compound of the formula:



R³ & R⁴ are independently H, C₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁷, R⁸ are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected from N, O, S, such as pyrrolidine, piperidine, Δ³-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl, or substituted on nitrogen with C₁₋₄alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl;


R^{11} is C_{1-3} alkyl, phenyl or a monocyclic heteroaromatic ring which can be unsubstituted or substituted with C_{1-4} alkyl, halogen, OC_{1-4} alkyl;

R^{12} is C_{1-4} alkyl or a fused bicyclic heteroaromatic ring such as thieno[3,2-e]-1,2-thiazine, or 1,2-benzothiazine, or R^{12} can be joined to R^{11} to form a fused bicyclic ring system such as 2,3-dihydro-benzo[c]isoxazole;

n is 2 to 4

and any pharmaceutically acceptable salts and solvates.

43. A composition comprising a pharmaceutically effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R^1 is H, OH, OC_{1-3} alkyl, C_{1-3} alkyl, C_{1-3} alkyl substituted optionally with OH, or OC_{1-3} alkyl;

R^2 is H, halogen, C_{1-3} alkyl, $CONR^5R^6$, $S(=O)_mC_{1-3}$ alkyl, $S(=O)_2NR^5R^6$, C_{1-3} alkyl substituted optionally with OH, or OC_{1-3} alkyl;

R^3 , R^4 are independently H, C_{1-3} alkyl, C_{1-3} alkyl substituted optionally with OH or OC_{1-3} alkyl;

R^5 , R^6 are independently H, C_{1-3} alkyl, C_{2-3} alkyl substituted optionally with OH, OC_{1-3} alkyl, or

R^5 and R^6 can be joined together with saturated carbon atoms to form a 5 or 6 membered ring and said carbon atoms can be either unsubstituted or substituted optionally with C_{1-3} alkyl, C_{2-3} alkyl substituted optionally with OH or OC_{1-3} alkyl;

R^7 , R^8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected from N, O, S, such as pyrrolidine, piperidine, Δ^3 -piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C_{1-3} alkyl, C_{1-3} alkyl substituted optionally with OH, OC_{1-3} alkyl, phenyl which can be unsubstituted or substituted


optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl, or substituted on nitrogen with C₁₋₄alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl;

n is 2 to 4;

m is 0, 1 or 2

and any pharmaceutically acceptable salts and solvates in a pharmaceutically acceptable carrier.

44. A composition comprising a pharmaceutically effective amount of a compound of the formula:



Wherein the dashed bond represents a single or double bond;

Aryl signifies a fused phenyl or monocyclic heteroaromatic ring;

R¹ is H, C₁₋₅alkyl, C₃₋₅alkenyl, an aromatic ring such as phenyl, thienyl, pyridyl, and imidazolyl which is either unsubstituted or substituted optionally with OH, OC₁₋₃alkyl, S(=O)_mC₁₋₃alkyl, halogen, CF₃, or S(=O)₂NR⁵R⁶; or C₂₋₅alkyl substituted optionally with OH, OC₁₋₃alkyl, S(=O)_mC₁₋₃alkyl or an aromatic ring such as phenyl, thienyl, pyridyl, and imidazolyl which is either unsubstituted or substituted optionally with OH, OC₁₋₃alkyl, S(=O)_mC₁₋₃alkyl, halogen, CF₃, S(=O)₂NR⁵R⁶; or C₃₋₅alkenyl substituted optionally with OH, OC₁₋₃alkyl, or S(=O)_mC₁₋₃alkyl;

R² is H, halogen, C₁₋₃alkyl, S(=O)_mC₁₋₃alkyl, S(=O)₂NR⁵R⁶, or C₁₋₃alkyl substituted optionally with OH, or OC₁₋₃alkyl;

R³ & R⁴ are independently H, C₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁵, R⁶ are independently H, C₁₋₃alkyl, C₂₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, or R⁵ and R⁶ can be joined together with saturated carbon atoms to form a 5 or 6


membered ring and said carbon atoms can be either unsubstituted or substituted optionally with C₁₋₃alkyl, C₂₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl; R⁷, R⁸ are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected from N, O, S, such as pyrrolidine, piperidine, Δ³-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl, or substituted on nitrogen with C₁₋₄alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl;

n is 2 to 4;

m is 0, 1 or 2

and any pharmaceutically acceptable salts and solvates in a pharmaceutically acceptable carrier.

45. A composition comprising a pharmaceutically effective amount of a compound of the formula:



R³ & R⁴ are independently H, C₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁷, R⁸ are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected from N, O, S, such as pyrrolidine, piperidine, Δ³-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl, or substituted on nitrogen

with C₁₋₄alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl;


R⁹ is phenyl or a monocyclic heteroaromatic ring which can be unsubstituted or substituted with C₁₋₄ alkyl, halogen, OC₁₋₄alkyl;

R¹⁰ is C₁₋₄alkyl, or R¹⁰ can be joined to R⁹ to form a fused bicyclic ring system such as indoline;

n is 2 to 4

and any pharmaceutically acceptable salts and solvates in a pharmaceutically acceptable carrier.

46. A composition comprising a pharmaceutically effective amount of a compound of the formula:



R³ & R⁴ are independently H, C₁₋₃alkyl, or C₁₋₃alkyl substituted optionally with OH or OC₁₋₃alkyl;

R⁷, R⁸ are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring of 5 to 8 atoms which may include a second heteroatom selected from N, O, S, such as pyrrolidine, piperidine, Δ³-piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C₁₋₃alkyl, C₁₋₃alkyl substituted optionally with OH, OC₁₋₃alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl, or substituted on nitrogen with C₁₋₄alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF₃, OC₁₋₃alkyl, or C₁₋₃alkyl;

R¹¹ is C₁₋₃alkyl, phenyl or a monocyclic heteroaromatic ring which can be unsubstituted or substituted with C₁₋₄ alkyl, halogen, OC₁₋₄alkyl;

R¹² is C₁₋₄alkyl or a fused bicyclic heteroaromatic ring such as thieno[3,2-*e*]-1,2-thiazine, or 1,2-benzothiazine, or R¹² can be joined to R¹¹ to form a fused bicyclic ring system such as 2,3-dihydro-benzo[*c*]isoxazole;

n is 2 to 4

and any pharmaceutically acceptable salts and solvates in a pharmaceutically acceptable carrier.

47. The Compound of Claim 1 selected from the group consisting of:

6-Chloro-2-[4-[4-(2*H*-benzimidazo-2-oxo-1-yl)piperidin-1-yl]butyl]-2*H*-thieno[3,2-*e*]-1,2-thiazine 1,1-dioxide;

6-Chloro-2-[4-(4-phenylpiperazin-1-yl)butyl]-2*H*-thieno[3,2-*e*]-1,2-thiazine 1,1-dioxide;

6-Chloro-2-[4-[4-(2-fluorophenyl)piperazin-1-yl]butyl]-2*H*-thieno[3,2-*e*]-1,2-thiazine 1,1-dioxide;

6-Chloro-2-[3-[4-(3-trifluoromethylphenyl)piperazin-1-yl]propyl]-2*H*-thieno[3,2-*e*]-1,2-thiazine 1,1-dioxide;

6-Chloro-2-[3-[4-(2*H*-benzimidazol-2-oxo)piperidin-1-yl]propyl]-2*H*-thieno[3,2-*e*]-1,2-thiazine 1,1-dioxide.

48. The Compound of Claim 3 selected from the group consisting of:

3-[4-(3-Chlorophenyl)piperazin-1-yl]propylsulfonyl-2,3-dihydro-1*H*-indole;

3-(1,2,3,4-Tetrahydroisoquinolin-2-yl)propylsulfonyl-2,3-dihydro-1*H*-indole;

3-[4-(3-Trifluoromethylphenyl)piperazin-1-yl]propylsulfonyl-2,3-dihydro-1*H*-indole;

3-[4-(2-Methoxyphenyl)piperazin-1-yl]propylsulfonyl-2,3-dihydro-1*H*-indole;

3-(1,2,3,4-Tetrahydroisoquinolin-2-yl)-*N*-methyl-*N*-phenyl-propylsulfonamide;

49. The Compound of Claim 4 selected from the group consisting of:

N-[3-[4-(3-Chlorophenyl)piperazin-1-yl]propyl]-*N*-(4-methoxyphenyl)-propanesulfonamide;

N-[3-(1,2,3,4-Tetrahydroisoquinolin-2-yl)propyl]-*N*-(4-methoxyphenyl)-propanesulfonamide;

N-[3-[4-(3-Chlorophenyl)piperazin-1-yl]propyl]-*N*-(4-methoxyphenyl)-propanesulfonamide;

N-[3-[4-(2-Methoxyphenyl)piperazin-1-yl]propyl]-*N*-(4-methoxyphenyl)-propanesulfonamide;

N-[3-[4-(2-Chlorophenyl)piperazin-1-yl]propyl]-*N*-(4-methoxyphenyl)-propanesulfonamide.